Thapsigargin resistance in human prostate cancer cells

Cancer

Volumn 107, Issue 3, 2006, Pages 649-659

  O'Neill, John P ^a   Velalar, Chidambaram Natesa ^a   Lee, Dong Ik ^a   Zhang, Bin ^a   Nakanishi, Takeo ^a   Tang, Yao ^a   Selaru, Florin ^a   Ross, Douglas ^a,b   Meltzer, Stephen J ^a,b   Hussain, Arif ^a,b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Calcium; Drug resistance; Microarray; Prostate cancer; Thapsigargin

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); COMPLEMENTARY DNA; GLYCOPROTEIN P; SARCOPLASMIC ENDOPLASMIC RETICULUM ADENOSINE TRIPHOSPHATASE (CALCIUM); THAPSIGARGIN; UNCLASSIFIED DRUG;

ADAPTATION; ARTICLE; CALCIUM HOMEOSTASIS; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESISTANCE; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CRICETINAE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THAPSIGARGIN; UP-REGULATION;

EID: 33746308216     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22027     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, et al. American Cancer Society Cancer Statistics 2005. CA Cancer J Clin. 2005;55:10-30.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
4. Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol Ther. 2005;4:14-22.
5. 2+ ATPases in cell function and the cellular consequences of their inhibition. J Membr Biol. 1999;172:91-99.
6. Furuya Y, Lundmo P Short AD, et al. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res. 1994;54:6167-6175.
7. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostate cancer cells induced by thapsigargin. Prostate. 1997;33:201-207.
8. Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostate cancer cells. Prostate. 2000;43:303-317.
9. Wertz IE, Dixit VM. Characterization of calcium release-activated apoptosis of LNCaP prostate cancer cells. J Biol Chem. 2000;275:11470-11477.
10. He Q, Lee DI, Rong R, et al. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene. 2002;21:2623-2633.
11. He Q, Montalbano J, Corcoran C, et al. Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis. Oncogene. 2003;22:2674-2679.
12. 2+ transport ATPase by thapsigargin at subnanomolar concentrations. J Biol Chem. 1991;266:13503-13506.
13. Denmeade SR, Isaacs JT. Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Cancer J Sci Am. 1998;(Suppl 1):S15-S21.
14. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003;95:990-2000.
15. 2+ transport ATPase and p-glycoprotein expression can mediate resistance to thapsigargin. J Biol Chem. 1994;269:7976-7981.
16. 2+ transport ATPase in the development of thapsigargin resistance by Chinese hamster lung fibroblasts. J Biol Chem. 1995;270:12140-12146.
17. 2+ transport ATPase in thapsigargin-resistant hamster smooth muscle cells. Nucleic Acids Res. 1998;26:4529-4537.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
19. Selaru FM, Zou T, Xu Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene. 2002;21:475-478.
20. Rasmussem R. Quantification on the lightcycler. In: Meur S, Wittwer C, Nakagawara K, eds. Rapid Cycle Real-Time PCR. Berlin: Springer, 2000:21-34.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:2002-2007.
22. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999;59:1391-1399.
23. Khatri P, Draghici S, Ostermeier GC, et al. Profiling gene expression using Onto-express. Genomics. 2002;79:266-270.
24. Bouras T, Southey MC, Chang AC, et al. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 2002;62:1289-1295.
25. Charpentier AH, Bednarek AK, Daniel RL, et al. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res. 2000;60:5977-5983.
26. Ciarmela P, Florio P, Sigurdardottir M, et al. Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinoma. Eur J Endocrinol. 2004;151:251-257.
27. Silva CC, Groome NP, Knight PG. Immunohistochemical localization of inhibin/activin alpha, betaA and betaB subunits and follistatin in bovine oocytes during in vitro maturation and fertilization. Reproduction. 2003;125:33-42.
28. Tirasophon W, Welihinda AA, Kaufman RJ. A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Irelp) in mammalian cells. Genes Dev. 1998;12:1812-1824.
29. Rutkowski DT, Kaufman RJ. All roads lead to ATF4. Dev Cell. 2003;4:442-444.
30. Wang Y, Shen J, Arenzana N, Tirasophon W, Kaufman RJ, Prywes R. Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response. J Biol Chem. 2000;275:27013-27020.
31. Sun S, Han J, Ralph WMJ, et al. Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell Stress Chaperones. 2004;9:76-87.
32. Rao RV, Hermel E, Castro-Obregon S, et al. Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem. 2001;276:33869-33874.
33. Yamaguchi H, Wang H-G. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 2004;279:45495-45502.
34. Putney JW Jr., Broad LM, Braun F-J, Lievremont J-P, Bird GSJ. Mechanisms of capacitative calcium entry. J Cell Sci. 2001;114:2223-2229.
35. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate. 1990;17:175-187.
36. 2+-induced apoptosis through calcineurin ephosphorylation of BAD. Science. 1999;284:339-343.
37. Chaudhary KS, Abel PD, Stamp GWH, Lalani E. Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol. 2001;193:522-529.
38. Chang SE, Littlefield JW. Elevated dihydrofolate reductase messenger RNA levels in methotrexate-resistant BHK cells. Cell. 1976;7:391-396.
39. Iemura SI, Yamamoto TS, Takagi C, et al. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci U S A. 1998;95:9337-9342.
40. McPherson SJ, Thomas TZ, Wang H, et al. Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol. 1997;154:535-545.